Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.46 |
| ▸ | ADA | P00813 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.35 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481579 | 0.87 | ADORA2A (0.49) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL12031227 | 0.86 | ADORA2A (0.53) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL12154572 | 0.86 | ADORA2A (0.53) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL474846 | 0.86 | ADORA2A (0.53) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL12150880 | 0.86 | ADORA2A (0.53) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL6730328 | 0.84 | ADORA2A (0.53) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL1737904 | 0.84 | ADORA2A (0.53) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL6727054 | 0.83 | ADORA3 (0.52) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL732950 | 0.83 | ADORA3 (0.52) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL6385081 | 0.82 | ADORA2A (0.64) | ADORA2AADAADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1267446-C | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO INC (US) | 2006-08-02 | — | — | CN | claimed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | claimed |
| CN-101228181-B | Hcv ns3 protease inhibitors | MERCK SHARP & DOHME | 2013-09-18 | — | — | CN | disclosed |
| CN-102159285-A | Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors | MERCK & CO INC | 2011-08-17 | — | — | CN | disclosed |
| CN-101611039-A | HCV NS3 protease inhibitors | MERCK & CO INC (US) | 2009-12-23 | — | — | CN | disclosed |
| CN-101583372-A | HCV NS3 protease inhibitors | MERCK & CO INC (US) | 2009-11-18 | — | — | CN | disclosed |
| CN-101568346-A | Hcv ns3 protease inhibitors | MERCK & CO INC (US) | 2009-10-28 | — | — | CN | disclosed |
| CN-101233148-A | Macrocyclic peptides as HCV NS3 protease inhibitors | MERCK & CO INC (US) | 2008-07-30 | — | — | CN | disclosed |
| CN-101228181-A | HCV NS3 protease inhibitors | MERCK & CO INC (US) | 2008-07-23 | — | — | CN | disclosed |
| CN-1267446-C | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO INC (US) | 2006-08-02 | — | — | CN | disclosed |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN | 2005-12-08 | — | — | US | disclosed |
| CN-1498221-A | Nucleoside derivatives as inhibitors of RNA-dependent PNA viral polymerase | — | 2004-05-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885ADA 145/4885ADORA3 334/4885 |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885ADA 145/4885ADORA3 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.